

# Pichai Raman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/932303/publications.pdf>

Version: 2024-02-01

61  
papers

13,993  
citations

147801

31  
h-index

206112

48  
g-index

64  
all docs

64  
docs citations

64  
times ranked

28685  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>MYC</i> Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 542-561.	9.4	35
2	Targeted gene expression profiling of inverted papilloma and squamous cell carcinoma. <i>International Forum of Allergy and Rhinology</i> , 2022, 12, 200-209.	2.8	8
3	IMMU-04. Transcriptional analysis reveals distinct microenvironmental subgroups across pediatric nervous system tumors. <i>Neuro-Oncology</i> , 2022, 24, i81-i81.	1.2	0
4	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	2.1	51
5	Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality. <i>Cell Reports</i> , 2021, 34, 108917.	6.4	27
6	OMIC-14. OPENPBTA: AN OPEN PEDIATRIC BRAIN TUMOR ATLAS. <i>Neuro-Oncology</i> , 2021, 23, i40-i40.	1.2	1
7	Pediatric high-grade glioma resources from the Children's Brain Tumor Tissue Consortium. <i>Neuro-Oncology</i> , 2020, 22, 163-165.	1.2	29
8	Diagnosing Cornelia de Lange syndrome and related neurodevelopmental disorders using RNA sequencing. <i>Genetics in Medicine</i> , 2020, 22, 927-936.	2.4	34
9	Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. <i>Cell</i> , 2020, 183, 1962-1985.e31.	28.9	177
10	annoFuse: an R Package to annotate, prioritize, and interactively explore putative oncogenic RNA fusions. <i>BMC Bioinformatics</i> , 2020, 21, 577.	2.6	4
11	Selective inhibition of TGF $\beta$ 1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	153
12	Immunogenicity and Immune Silence in Human Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 69.	4.8	22
13	CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 302.	2.8	13
14	RET receptor expression and interaction with TRK receptors in neuroblastomas. <i>Oncology Reports</i> , 2020, 44, 263-272.	2.6	6
15	A transcriptome-based classifier to determine molecular subtypes in medulloblastoma. <i>PLoS Computational Biology</i> , 2020, 16, e1008263.	3.2	6
16	TMOD-18. AN INTEGRATED SET OF PEDIATRIC HIGH GRADE GLIOMA RESOURCES FOR TRANSLATIONAL STUDIES. <i>Neuro-Oncology</i> , 2019, 21, ii124-ii125.	1.2	0
17	TMOD-19. GABRIELLA MILLER KIDS FIRST DATA RESOURCE CENTER: LARGE-SCALE HARMONIZED CLINICAL AND GENOMIC DATA PLATFORM TO SUPPORT CHILDHOOD CANCER AND STRUCTURAL BIRTH DEFECT RESEARCH. <i>Neuro-Oncology</i> , 2019, 21, ii125-ii125.	1.2	0
18	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. <i>Cell Reports</i> , 2019, 29, 1675-1689.e9.	6.4	103

#	ARTICLE	IF	CITATIONS
19	DIPG-30. ISOFORM SPECIFIC OVEREXPRESSION OF WILMSâ€™ TUMOR PROTEIN IN DIFFUSE INTRINSIC PONTINE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, ii75-ii75.	1.2	0
20	Clinical utility of custom-designed NGS panel testing in pediatric tumors. <i>Genome Medicine</i> , 2019, 11, 32.	8.2	79
21	DIPG-35. OPEN DIPG INITIATIVE: A PLATFORM FOR ACCELERATING DISCOVERY THROUGH DATA ACCESS, CONSOLIDATION AND HARMONIZATION. <i>Neuro-Oncology</i> , 2019, 21, ii76-ii76.	1.2	0
22	GENE-19. DEEP PROTEOMIC SURVEY ACROSS SEVEN CHILDHOOD BRAIN TUMORS. <i>Neuro-Oncology</i> , 2019, 21, ii85-ii85.	1.2	0
23	TMOD-20. THE PEDIATRIC BRAIN TUMOR ATLAS: AN INITIATIVE BY THE CHILDRENâ€™S BRAIN TUMOR TISSUE CONSORTIUM AND PACIFIC PEDIATRIC NEUROONCOLOGY CONSORTIUM. <i>Neuro-Oncology</i> , 2019, 21, ii125-ii125.	1.2	0
24	Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1195-1204.	4.1	36
25	IMMU-01. NOVEL RNA-TARGETING STRATEGY FOR TREATING T CELL-DRIVEN IMMUNOSUPPRESSION IN HUMAN DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, ii92-ii93.	1.2	2
26	An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	44
27	A comparison of survival analysis methods for cancer gene expression RNA-Sequencing data. <i>Cancer Genetics</i> , 2019, 235-236, 1-12.	0.4	11
28	The Pediatric Cell Atlas: Defining the Growth Phase of Human Development at Single-Cell Resolution. <i>Developmental Cell</i> , 2019, 49, 10-29.	7.0	57
29	PDTM-16. PEDIATRIC HIGH GRADE GLIOMA RESOURCES FROM THE CHILDRENâ€™S BRAIN TUMOR TISSUE CONSORTIUM (CBTTC) AND PEDIATRIC BRAIN TUMOR ATLAS (PBTA). <i>Neuro-Oncology</i> , 2019, 21, vi190-vi190.	1.2	1
30	Pediatric Somatic Tumor Sequencing Identifies Underlying Cancer Predisposition. <i>JCO Precision Oncology</i> , 2019, 3, 1-26.	3.0	6
31	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , 2018, 555, 321-327.	27.8	1,068
32	Aggressive triple negative breast cancers have unique molecular signature on the basis of mitochondrial genetic and functional defects. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1060-1071.	3.8	57
33	TBIO-29. PedcBioPortal, A CANCER DATA VISUALIZATION TOOL FOR INTEGRATIVE PEDIATRIC CANCER ANALYSES. <i>Neuro-Oncology</i> , 2018, 20, i186-i186.	1.2	0
34	PDTM-10. NOVEL RNA-TARGETING STRATEGY FOR TREATING T CELL-DRIVEN IMMUNOSUPPRESSION IN HUMAN DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi205-vi206.	1.2	0
35	HGG-33. PATIENT DERIVED CELL LINES TO STUDY ATRX AND ALT IN PEDIATRIC BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018, 20, i96-i96.	1.2	0
36	TBIO-27. GABRIELLA MILLER KIDS FIRST DATA RESOURCE CENTER ADVANCING GENETIC RESEARCH IN CHILDHOOD CANCER AND STRUCTURAL BIRTH DEFECTS THROUGH LARGE SCALE INTEGRATED DATA-DRIVEN DISCOVERY AND CLOUD-BASED PLATFORMS FOR COLLABORATIVE ANALYSIS. <i>Neuro-Oncology</i> , 2018, 20, i186-i186.	1.2	0

#	ARTICLE	IF	CITATIONS
37	TBIO-28. DISEASEXPRESS, A CANCER DATA ANALYTICS AND VISUALIZATION TOOL FOR IDENTIFYING IMMUNOTHERAPEUTIC TARGETS IN PEDIATRIC BRAIN TUMORS AND OTHER CANCERS. <i>Neuro-Oncology</i> , 2018, 20, i186-i186.	1.2	0
38	Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. <i>Cancer Cell</i> , 2018, 33, 829-842.e5.	16.8	140
39	Pancreatic cancer survival analysis defines a signature that predicts outcome. <i>PLoS ONE</i> , 2018, 13, e0201751.	2.5	75
40	Transcriptome analysis of IL-10-stimulated (M2c) macrophages by next-generation sequencing. <i>Immunobiology</i> , 2017, 222, 847-856.	1.9	142
41	Rb family proteins enforce the homeostasis of quiescent hematopoietic stem cells by repressing Socs3 expression. <i>Journal of Experimental Medicine</i> , 2017, 214, 1901-1912.	8.5	13
42	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. <i>Cancer Cell</i> , 2017, 32, 520-537.e5.	16.8	716
43	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	28.9	596
44	Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. <i>Cancer Cell</i> , 2017, 32, 295-309.e12.	16.8	148
45	The functional variant rs34330 of <i>CDKN1B</i> is associated with risk of neuroblastoma. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 3224-3230.	3.6	47
46	Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. <i>Clinical Cancer Research</i> , 2017, 23, 1785-1796.	7.0	66
47	Overcoming resistance to single-agent therapy for oncogenic <i>BRAF</i> gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. <i>Oncotarget</i> , 2017, 8, 84697-84713.	1.8	38
48	Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 948-960.	7.0	86
49	Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome. <i>PLoS Genetics</i> , 2016, 12, e1006501.	3.5	98
50	FXD5 is a Marker for Poor Prognosis and a Potential Driver for Metastasis in Ovarian Carcinomas. <i>Cancer Informatics</i> , 2015, 14, CIN.S30565.	1.9	14
51	Recruitment of Pontin/Reptin by E2f1 amplifies E2f transcriptional response during cancer progression. <i>Nature Communications</i> , 2015, 6, 10028.	12.8	52
52	Genomic and functional comparison of mesenchymal stromal cells prepared using two isolation methods. <i>Cytotherapy</i> , 2015, 17, 262-270.	0.7	17
53	CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. <i>Cancer Research</i> , 2015, 75, 3155-3166.	0.9	132
54	A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis. <i>Cancer Cell</i> , 2015, 28, 599-609.	16.8	99

#	ARTICLE	IF	CITATIONS
55	Convergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy. <i>Cancer Discovery</i> , 2015, 5, 1282-1295.	9.4	997
56	Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation. <i>PLoS ONE</i> , 2015, 10, e0127498.	2.5	86
57	Abstract B34: Antitumor activity and sensitivity evaluation of novel BET inhibitors in neuroblastoma. , 2015, , .		0
58	Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E1026-34.	7.1	265
59	The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. <i>Nature</i> , 2012, 483, 603-607.	27.8	6,473
60	Compound Set Enrichment: A Novel Approach to Analysis of Primary HTS Data. <i>Journal of Chemical Information and Modeling</i> , 2010, 50, 2067-2078.	5.4	48
61	Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1. <i>Molecular Cell</i> , 2010, 39, 171-183.	9.7	1,598